

Forms are available in the application kit and at the following Internet address: [www.cdc.gov/od/pgo/forminfo.htm](http://www.cdc.gov/od/pgo/forminfo.htm).

On or before July 15, 2002, 5:00 pm Eastern Time, submit the application to: Technical Information Management Section-PA 02089, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146.

Applications will be considered as meeting the deadline if they are received on or before the deadline date. Late applications will be returned to the applicant.

#### G. Evaluation Criteria

Each application will be evaluated individually against the following criteria by an Independent Review Group appointed by CDC.

##### 1. Background and Need (20 points)

The extent to which the applicant understands the needs, problems, objectives and complexities of the program.

##### 2. Objectives (15 points)

The extent to which the proposed objectives are clearly stated, realistic, time-phased, and related to the purpose of the project.

##### 3. Operational Plan (25 points)

The extent to which the applicant provides a detailed plan of proposed activities which are likely to achieve each objective and overall program goals. The extent to which the applicant provides a reasonable and complete schedule for implementing activities of the program.

##### 4. Evaluation Plan (15 points)

The extent to which the proposed evaluation plan is detailed, addresses goals and objectives of the program, and will document the program process, effectiveness and outcome. The extent to which a feasible plan for reporting evaluation results and using evaluation information for programmatic decisions is present.

##### 5. Program Management (20 points)

a. The extent to which the applicant proposes potentially effective collaborations with treatment centers. (10 points)

b. The extent to which professional personnel proposed to be involved in this project are qualified, including evidence of past achievements appropriate to this project. (10 points)

##### 6. Measures of Effectiveness (5 points)

The extent to which the applicant provide Measures of Effectiveness that

will demonstrate the accomplishment of the various identified objectives of the grant. Are the measures objective/quantitative and do they adequately measure the intended outcome?

##### 7. Budget (Not scored)

The extent to which the applicant provides a detailed budget and narrative justification consistent with stated objectives and planned program activities.

#### H. Other Requirements

##### Technical Reporting Requirements

Provide CDC with original plus two copies of

1. Semiannual progress reports;
2. Financial status report, no more than 90 days after the end of the budget period; and
3. Final financial report and performance report, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I of the announcement.

AR-10 Smoke-Free Workplace Requirements

AR-11 Healthy People 2010

AR-12 Lobbying Restrictions

AR-15 Proof of Non-Profit Status

#### I. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under section 301(a) [42 U.S.C. 241(a)] and 317 (k)(2) [42 U.S.C. 247b(k)(2)] of the Public Health Service Act, as amended. The Catalog of Federal Domestic Assistance number is 93.283.

#### J. Where To Obtain Additional Information

This and other CDC announcements can be found on the CDC home page Internet address—<http://www.cdc.gov>. Click on "Funding" then "Grants and Cooperative Agreements."

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from: Merlin Williams, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Mailstop K-75, Atlanta, GA 30341-4146. Telephone number: 770-488-2765. E-mail address: [mwilliams2@cdc.gov](mailto:mwilliams2@cdc.gov).

For program technical assistance, contact: Sally Crudder, Acting Deputy Chief, Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, N.E. Mailstop E-64, Atlanta, Georgia 30333. Telephone number: 404-371-5270 or 5903. E-mail address: [scrudder@cdc.gov](mailto:scrudder@cdc.gov).

Dated: April 26, 2002.

**Sandra R. Manning,**

*Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 02-10834 Filed 5-2-02; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Correction

**ACTION:** Notice; Correction.

In the **Federal Register** of April 17, 2002, Volume 67, Number 74, Page 18911 the following should read as follows:

#### Correction

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Centers for Disease Control and Prevention: Meeting

The Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

*Name:* Advisory Committee on Immunization Practices, Smallpox Working Group.

*Times and Dates:*

9 a.m.-12 p.m., May 8, 2002 (Closed).

1 p.m.-9 p.m., May 8, 2002.

8:30 a.m.-11:30 a.m., May 9, 2002.

*Place:* Atlanta Marriott Century Center, 2000 Century Boulevard, NE, Atlanta, Georgia 30345-3377.

*Status:* Closed 9 a.m.-12 p.m., May 8, 2002. Remainder of meeting open to the public, limited only by the space available.

*Purpose:* The working group will convene in closed session from 9 a.m.-12 a.m., May 8, 2002. During the open session the working group will gather information and formulate options to be presented to the Advisory Committee on Immunization Practices for its deliberation in making recommendations for the use of vaccinia (smallpox) vaccine.

*Matters To Be Discussed:* The panel will gather information regarding the use of vaccinia (smallpox) vaccine.

*Contact Person for More Information:* Gloria A. Kovach, Program Analyst, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE, m/s E61, Atlanta, Georgia 30333. Telephone 404/639-8096.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 29, 2002.

**John Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 02-10983 Filed 5-2-02; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Savannah River Site Health Effects Subcommittee (SRSHES)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), and the Agency for Toxic Substances and Disease Registry (ATSDR) announce the following meeting.

*Name:* Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Savannah River Site Health Effects Subcommittee (SRSHES).

*Time and Date:* 8:30 a.m.-4:45 p.m., June 6, 2002.

*Place:* Radisson Riverfront Hotel Augusta, 2 10th Street, Augusta, Georgia 30901, telephone (706) 722-8900, fax (706) 724-0044, [www.radisson.com](http://www.radisson.com).

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

*Background:* Under a Memorandum of Understanding (MOU) signed in December

1990 with DOE, and replaced by MOUs signed in 1996 and 2000, the Department of Health and Human Services (HHS) was given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production use. HHS delegated program responsibility to CDC.

In addition, a memo was signed in October 1990 and renewed in November 1992, 1996, and in 2000, between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or "Superfund"). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

*Purpose:* This subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, regarding community concerns pertaining to CDC's and ATSDR's public health activities and research at this DOE site. The purpose of this meeting is to provide a forum for community interaction and serve as a vehicle for community concerns to be expressed as advice and recommendations to CDC and ATSDR.

*Matters to be Discussed:* Agenda items include: Update on Department of Labor/Department of Energy Workers Occupational Illness Compensation Program; Overview of Process on Risk Based Screening Criteria and Where it is Going; International Atomic Energy Administration Recommendations; ATSDR Needs Assessment; American College of Preventive Medicine Initiatives Update; and ATSDR/Tritium Health Consult on Potential Tritium Exposures at SRS. Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Phillip Green, Executive Secretary, SRSHES, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 1600 Clifton Road, NE., (E-39), Atlanta, Georgia 30333, telephone (404) 498-1800, fax (404) 498-1811.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and ATSDR.

Dated: April 29, 2002.

**Alvin Hall,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 02-10985 Filed 5-2-02; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### An FDA/Industry Dialog on the Application Submission Process; Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshops.

The Food and Drug Administration (FDA) is announcing two public workshops, both entitled "An FDA/Industry Dialog on the Application Submission Process." The purpose of the public workshops is to discuss common application deficiencies and strategies to avoid these deficiencies leading to faster approval times. Staff from the Center for Biologics Evaluation and Research (CBER) will provide general information on the review process and options to consider. CBER staff also will lead discussion groups designed to respond to your general issues and questions on submission requirements. These discussion groups will be established based on the input provided to CBER on your issues relative to the purpose of this workshop.

*Date and Time:* Send registration and issues by May 17, 2002, for the May 29, 2002, workshop and by June 14, 2002, for the June 26, 2002, workshop. See table 1 of this document.

*Location:* See table 1 of this document.

TABLE 1

Meeting address	Dates and local time	FDA contact person
Hyatt Regency Bethesda, 1 Bethesda Metro Center, Bethesda, MD 20814, 301-657-1234.	May 29, 2002, from 9 a.m. to 5 p.m.	Kathy Eberhart.